Acute toxicity with intensity modulated radiotherapy versus 3-dimensional conformal radiotherapy during preoperative chemoradiation for locally advanced rectal cancer

Radiotherapy and Oncology

Volumn 121, Issue 2, 2016, Pages 252-257

  Ng, Shu Y ^a   Colborn, Kathryn L ^b   Cambridge, Lajhem ^a   Hajj, Carla ^a   Yang, T Jonathan ^a   Wu, Abraham J ^a   Goodman, Karyn A ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Intensity modulated radiotherapy; Locally advanced rectal cancer; Pelvic radiotherapy; Pre operative chemoradiation; Toxicity

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ABSENCE OF COMPLICATIONS; ACUTE TOXICITY; ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHEMORADIOTHERAPY; CLINICAL OUTCOME; CONFORMAL RADIOTHERAPY; DERMATITIS; DIARRHEA; FATIGUE; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROCTITIS; RECTUM CANCER; RETROSPECTIVE STUDY; SEX DIFFERENCE; VAGINA DISCHARGE; ACUTE DISEASE; ADJUVANT CHEMORADIOTHERAPY; ADVERSE EFFECTS; MIDDLE AGED; PATHOLOGY; PROCEDURES; RADIATION INJURIES; RADIATION RESPONSE; RADIOTHERAPY DOSAGE; RECTAL NEOPLASMS; RISK FACTOR; UROGENITAL SYSTEM; VERY ELDERLY; YOUNG ADULT;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; CHEMORADIOTHERAPY, ADJUVANT; DIARRHEA; FEMALE; HUMANS; MALE; MIDDLE AGED; PROCTITIS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; UROGENITAL SYSTEM; YOUNG ADULT;

EID: 84991203520     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2016.09.010     Document Type: Article

References (27)

1. [1] Bosset, J.-F., Collette, L., Calais, G., Mineur, L., Maingon, P., Radosevic-Jelic, L., et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355 (2006), 1114–1123.
2. [2] Gerard, J.P., Conroy, T., Bonnetain, F., Bouche, O., Chapet, O., Closon-Dejardin, M.T., et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol 24 (2006), 4620–4625.
3. [3] Sauer, R., Becker, H., Hohenberger, W., Rodel, C., Wittekind, C., Fietkau, R., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351 (2004), 1731–1740.
4. [4] Carlsen, E., Schlichting, E., Guldvog, I., Johnson, E., Heald, R.J., Effect of the introduction of total mesorectal excision for the treatment of rectal cancer. Br J Surg 85 (1998), 526–529.
5. [5] O'Connell, M.J., Colangelo, L.H., Beart, R.W., Petrelli, N.J., Allegra, C.J., Sharif, S., et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol 32 (2014), 1927–1934.
6. [6] Mohiuddin, M., Winter, K., Mitchell, E., Hanna, N., Yuen, A., Nichols, C., et al. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol 24 (2006), 650–655.
7. [7] Guren, M., Dueland, S., Skovlund, E., Fosså, S., Poulsen, J., Tveit, K., Quality of life during radiotherapy for rectal cancer. Eur J Cancer 39 (2003), 587–594.
8. [8] Mendenhall, W.M., Amdur, R.J., Palta, J.R., Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls. J Clin Oncol 24 (2006), 2618–2623.
9. [9] Milano, M.T., Jani, A.B., Farrey, K.J., Rash, C., Heimann, R., Chmura, S.J., Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 63 (2005), 354–361.
10. [10] Zelefsky, M.J., Fuks, Z., Happersett, L., Lee, H.J., Ling, C.C., Burman, C.M., et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 55 (2000), 241–249.
11. [11] Mundt, A.J., Lujan, A.E., Rotmensch, J., Waggoner, S.E., Yamada, S.D., Fleming, G., et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 52 (2002), 1330–1337.
12. [12] Tho, L.M., Glegg, M., Paterson, J., Yap, C., MacLeod, A., McCabe, M., et al. Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: investigating dose-volume relationships and role for inverse planning. Int J Radiat Oncol Biol Phys 66 (2006), 505–513.
13. [13] Arbea, L., Ramos, L.I., Martinez-Monge, R., Moreno, M., Aristu, J., Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications. Radiat Oncol, 5, 2010, 17.
14. [14] Mok, H., Crane, C.H., Palmer, M.B., Briere, T.M., Beddar, S., Delclos, M.E., et al. Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma. Radiat Oncol, 6, 2011, 63.
15. [15] Jabbour, S.K., Patel, S., Herman, J.M., Wild, A., Nagda, S.N., Altoos, T., et al. Intensity-modulated radiation therapy for rectal carcinoma can reduce treatment breaks and emergency department visits. Int J Surg Oncol, 2012, 2012, 891067.
16. [16] Parekh, A., Truong, M.T., Pashtan, I., Qureshi, M.M., Martin, N.E., Nawaz, O., et al. Acute gastrointestinal toxicity and tumor response with preoperative intensity modulated radiation therapy for rectal cancer. Gastrointest Cancer Res 6 (2013), 137–143.
17. [17] Samuelian, J.M., Callister, M.D., Ashman, J.B., Young-Fadok, T.M., Borad, M.J., Gunderson, L.L., Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 82 (2012), 1981–1987.
18. [18] Yang, T.J., Oh, J.H., Son, C.H., Apte, A., Deasy, J.O., Wu, A., et al. Predictors of acute gastrointestinal toxicity during pelvic chemoradiotherapy in patients with rectal cancer. Gastrointest Cancer Res 6 (2013), 129–136.
19. [19] Myerson, R.J., Garofalo, M.C., El Naqa, I., Abrams, R.A., Apte, A., Bosch, W.R., et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys 74 (2009), 824–830.
20. [20] R Core Team. Vienna, Austria: R Foundation for Statistical Computing; 2015.
21. [21] Hong, T.S., Moughan, J., Garofalo, M.C., Bendell, J., Berger, A.C., Oldenburg, N.B., et al. NRG Oncology Radiation Therapy Oncology Group 0822: A Phase 2 study of preoperative chemoradiation therapy using intensity modulated radiation therapy in combination with capecitabine and oxaliplatin for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 93 (2015), 29–36.
22. [22] Gerard, J.P., Azria, D., Gourgou-Bourgade, S., Martel-Lafay, I., Hennequin, C., Etienne, P.L., et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 30 (2012), 4558–4565.
23. [23] Aschele, C., Cionini, L., Lonardi, S., Pinto, C., Cordio, S., Rosati, G., et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 29 (2011), 2773–2780.
24. [24] Gundling, F., Seidl, H., Scalercio, N., Schmidt, T., Schepp, W., Pehl, C., Influence of gender and age on anorectal function: normal values from anorectal manometry in a large caucasian population. Digestion 81 (2010), 207–213.
25. [25] Yu, S.W., Rao, S.S., Anorectal physiology and pathophysiology in the elderly. Clin Geriatr Med 30 (2014), 95–106.
26. [26] Bosset, J.-F., Calais, G., Mineur, L., Maingon, P., Stojanovic-Rundic, S., Bensadoun, R.-J., et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 15 (2014), 184–190.
27. [27] Roh, M.S., Colangelo, L.H., O'Connell, M.J., Yothers, G., Deutsch, M., Allegra, C.J., et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 27 (2009), 5124–5130.